FY2024 EPS Forecast for Co-Diagnostics Increased by Analyst

Co-Diagnostics, Inc. (NASDAQ:CODX) – Investment analysts at HC Wainwright lifted their FY2024 EPS estimates for shares of Co-Diagnostics in a note issued to investors on Monday, November 11th. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($1.22) per share for the year, up from their prior estimate of ($1.23). HC Wainwright has a “Neutral” rating and a $1.50 price target on the stock. The consensus estimate for Co-Diagnostics’ current full-year earnings is ($1.23) per share. HC Wainwright also issued estimates for Co-Diagnostics’ Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($1.17) EPS.

Co-Diagnostics Price Performance

Shares of NASDAQ CODX opened at $1.11 on Thursday. Co-Diagnostics has a one year low of $1.00 and a one year high of $2.23. The firm has a market cap of $35.44 million, a price-to-earnings ratio of -0.80 and a beta of -0.84. The stock’s fifty day moving average price is $1.24 and its two-hundred day moving average price is $1.26.

Institutional Trading of Co-Diagnostics

A hedge fund recently bought a new stake in Co-Diagnostics stock. Koss Olinger Consulting LLC acquired a new position in shares of Co-Diagnostics, Inc. (NASDAQ:CODX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 58,887 shares of the company’s stock, valued at approximately $74,000. Koss Olinger Consulting LLC owned 0.19% of Co-Diagnostics at the end of the most recent reporting period. 14.99% of the stock is owned by institutional investors and hedge funds.

Co-Diagnostics Company Profile

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.